Cargando…

Natural Killer Cells Modulation in Hematological Malignancies

Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, us...

Descripción completa

Detalles Bibliográficos
Autores principales: Baier, Céline, Fino, Aurore, Sanchez, Carole, Farnault, Laure, Rihet, Pascal, Kahn-Perlès, Brigitte, Costello, Régis T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867693/
https://www.ncbi.nlm.nih.gov/pubmed/24391641
http://dx.doi.org/10.3389/fimmu.2013.00459
_version_ 1782296345245122560
author Baier, Céline
Fino, Aurore
Sanchez, Carole
Farnault, Laure
Rihet, Pascal
Kahn-Perlès, Brigitte
Costello, Régis T.
author_facet Baier, Céline
Fino, Aurore
Sanchez, Carole
Farnault, Laure
Rihet, Pascal
Kahn-Perlès, Brigitte
Costello, Régis T.
author_sort Baier, Céline
collection PubMed
description Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, using either drug maintenance treatment or by boosting or prolonging an immune response. Immune system has a key role in tumor surveillance. Nonetheless, tumor-cells evade the specific T-lymphocyte mediated immune surveillance using many mechanisms but especially by the down-regulation of the expression of HLA class I antigens. In theory, these tumor-cells lacking normal expression of HLA class I molecules should be destroyed by natural killer (NK) cells, according to the missing-self hypothesis. NK cells, at the frontier of innate and adaptive immune system, have a central role in tumor-cells surveillance as demonstrated in the setting of allogenic stem cell transplantation. Nevertheless, tumors develop various mechanisms to escape from NK innate immune pressure. Abnormal NK cytolytic functions have been described in many HM. We present here various mechanisms involved in the escape of HM from NK-cell surveillance, i.e., NK-cells quantitative and qualitative abnormalities.
format Online
Article
Text
id pubmed-3867693
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38676932014-01-03 Natural Killer Cells Modulation in Hematological Malignancies Baier, Céline Fino, Aurore Sanchez, Carole Farnault, Laure Rihet, Pascal Kahn-Perlès, Brigitte Costello, Régis T. Front Immunol Immunology Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, using either drug maintenance treatment or by boosting or prolonging an immune response. Immune system has a key role in tumor surveillance. Nonetheless, tumor-cells evade the specific T-lymphocyte mediated immune surveillance using many mechanisms but especially by the down-regulation of the expression of HLA class I antigens. In theory, these tumor-cells lacking normal expression of HLA class I molecules should be destroyed by natural killer (NK) cells, according to the missing-self hypothesis. NK cells, at the frontier of innate and adaptive immune system, have a central role in tumor-cells surveillance as demonstrated in the setting of allogenic stem cell transplantation. Nevertheless, tumors develop various mechanisms to escape from NK innate immune pressure. Abnormal NK cytolytic functions have been described in many HM. We present here various mechanisms involved in the escape of HM from NK-cell surveillance, i.e., NK-cells quantitative and qualitative abnormalities. Frontiers Media S.A. 2013-12-19 /pmc/articles/PMC3867693/ /pubmed/24391641 http://dx.doi.org/10.3389/fimmu.2013.00459 Text en Copyright © 2013 Baier, Fino, Sanchez, Farnault, Rihet, Kahn-Perlès and Costello. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Baier, Céline
Fino, Aurore
Sanchez, Carole
Farnault, Laure
Rihet, Pascal
Kahn-Perlès, Brigitte
Costello, Régis T.
Natural Killer Cells Modulation in Hematological Malignancies
title Natural Killer Cells Modulation in Hematological Malignancies
title_full Natural Killer Cells Modulation in Hematological Malignancies
title_fullStr Natural Killer Cells Modulation in Hematological Malignancies
title_full_unstemmed Natural Killer Cells Modulation in Hematological Malignancies
title_short Natural Killer Cells Modulation in Hematological Malignancies
title_sort natural killer cells modulation in hematological malignancies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867693/
https://www.ncbi.nlm.nih.gov/pubmed/24391641
http://dx.doi.org/10.3389/fimmu.2013.00459
work_keys_str_mv AT baierceline naturalkillercellsmodulationinhematologicalmalignancies
AT finoaurore naturalkillercellsmodulationinhematologicalmalignancies
AT sanchezcarole naturalkillercellsmodulationinhematologicalmalignancies
AT farnaultlaure naturalkillercellsmodulationinhematologicalmalignancies
AT rihetpascal naturalkillercellsmodulationinhematologicalmalignancies
AT kahnperlesbrigitte naturalkillercellsmodulationinhematologicalmalignancies
AT costelloregist naturalkillercellsmodulationinhematologicalmalignancies